- https://doi.org/10.2147/blctt.s527790
Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes.
Translate Article 
Take Notes Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for higher-risk myelodysplastic syndromes (MDS), but optimal timing and donor selection remain controversial. We conducted a retrospective analysis of 70higher-risk MDS patients classified by the revised International Prognostic Scoring System (IPSS-R) undergoing allo-HSCT. Patients were stratified by: 1) the interval from diagnosis to allo-HSCT (early: <6 months vs later: ≥6 months); 2) pre-transplant treatment cycles (fewer: <2 vs more: ≥2); 3) remission status (complete remission [CR] / partial remission [PR] vs non-remission [NR]), and 4) donor type (sibling vs unrelated cord blood [UCB]). The results showed a significantly higher 3-year overall survival (OS) in the early HSCT group (70% vs 50%, p = 0.05) with lower transplant-related mortality (TRM) (22.7% vs 46.5%, p = 0.0205). Although more pre-transplant treatment cycles were linked to a lower relapse rate (2.3% vs 15.4%, p = 0.0403), they did not significantly affect OS or TRM. Early HSCT emerged as the only significant factor influencing both OS (Hazard Ratio [HR] 2.84, p = 0.01) and TRM (HR 3.21, p = 0.01). While no significant differences were noted between sibling HSCT and unrelated cord blood transplantation (UCBT) for OS and TRM, UCBT demonstrated a lower incidence of chronic graft-versus-host disease (cGVHD) (19.0% vs 52.9%, p = 0.003). Our findings suggest early allo-HSCT may optimize outcomes in higher-risk MDS. In settings where sibling donors are unavailable, UCBT could serve as a potential alternative, though this observation requires validation in prospective multicenter studies to account for inherent selection biases and confounding factors.
- # Transplant-related Mortality
- # Allogeneic Hematopoietic Stem Cell Transplantation
- # Revised International Prognostic Scoring System
- # Unrelated Cord Blood Transplantation
- # Myelodysplastic Syndromes
- # Lower Transplant-related Mortality
- # Early HSCT
- # Higher-risk Myelodysplastic Syndromes
- # Unrelated Cord Blood
- # Sibling HSCT
- Research Article
69 - 10.1016/j.bbmt.2011.10.008
- Oct 17, 2011
- Biology of Blood and Marrow Transplantation
Comparison of Unrelated Cord Blood Transplantation and HLA-Mismatched Unrelated Bone Marrow Transplantation for Adults with Leukemia
- Research Article
- 30
- 10.1016/j.exphem.2012.06.003
- Jun 12, 2012
- Experimental Hematology
Impact of anti-HLA antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens
- Research Article
- 60
- 10.1016/j.exphem.2008.01.017
- Mar 17, 2008
- Experimental Hematology
Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire
- Research Article
- 31
- 10.1016/j.bbmt.2011.05.015
- May 27, 2011
- Biology of Blood and Marrow Transplantation
CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus
- Research Article
- 28
- 10.1016/j.bbmt.2011.06.010
- Jun 30, 2011
- Biology of Blood and Marrow Transplantation
EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation Procedure
- Research Article
- 12
- 10.1002/ajh.26839
- Jan 24, 2023
- American Journal of Hematology
Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real-world registry study in Japan.
- Research Article
- 21
- 10.1016/j.bbmt.2017.03.014
- Mar 10, 2017
- Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes
- Abstract
- 2
- 10.1182/blood.v118.21.1709.1709
- Nov 18, 2011
- Blood
Prognostic Effect of ASXL1 Mutations in Patients with MDS and Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation
- Abstract
- 1
- 10.1182/blood.v126.23.2003.2003
- Dec 3, 2015
- Blood
Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes: A Center for International Blood and Marrow Transplant Registry (CIBMTR®) Study
- Abstract
- 10.1182/blood-2023-185976
- Nov 28, 2023
- Blood
Venetoclax+Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes
- Abstract
- 10.1182/blood-2018-99-120166
- Nov 29, 2018
- Blood
Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience
- Research Article
- 44
- 10.1016/j.bbmt.2005.10.005
- Jan 1, 2006
- Biology of Blood and Marrow Transplantation
Advances in HLA: Practical Implications for Selecting Adult Donors and Cord Blood Units
- Abstract
- 2
- 10.1182/blood.v128.22.69.69
- Dec 2, 2016
- Blood
Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation
- Research Article
- 20
- 10.1002/ajh.26539
- Mar 24, 2022
- American Journal of Hematology
Real‐world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts
- Front Matter
- 22
- 10.1111/bjh.17612
- Jun 27, 2021
- British Journal of Haematology
British Society for Haematology guidelines for the management of adult myelodysplastic syndromes.
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
What is the difference between bacteria and viruses?
What is the function of the immune system?Can diabetes be passed down from one generation to the next?